An article published in the journal Haemophilia covers the many accomplishments the WFH Humanitarian Aid Program made possible in 2016. In “First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries” (G. F. Pierce et al, Haemophilia. 2018;24:229-235) readers have the chance to learn about the achievements of the WFH Humanitarian Aid Program in 2016—a year after the program’s scope was expanded. Along with contributions by WFH staff and volunteers, Glenn Pierce, MD, PhD, WFH Vice-President Medical, explores the situation in recipient countries before the expansion of this program and highlights how these countries could now respond to the treatment needs more effectively due to the increased predictability of donations. To read the full article, please click here.
About the WFH Humanitarian Aid Program
The expanded WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Visionary Contributors; Grifols, CSL Behring, GC Pharma, our Corporate partners; and Roche and Bayer, our newest donors. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org